Journal Article

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

Gupta, Ravindra K., Hill, Andrew, de Oliveira, Tulio, Moorhouse, Michelle A., Chimukangara, Benjamin, Kemp, Stephen A., Giandhari, Jennifer, Serenata, Celicia M., Akpomiemie, Godspower, Simmons, Bryony, Lessells, Richard, Venter, Willem D. F., Siedner, Mark J.

2020

Overview

Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment plasma specimens from the ADVANCE trial (NCT03122262). Our primary outcome was 96-week virologic success, defined as a sustained viral load <1000 copies/mL from 12 weeks onwards, <200 copies/mL from 24 weeks onwards, and <50 copies/mL after 48 weeks. Here we report how this outcome was impacted by PDR, defined by the World Health Organization (WHO) mutation list. Of 1053 trial participants, 874 (83%) have successful sequencing, including 289 (33%) randomized to EFV-based therapy and 585 (67%) randomized to DTG-based therapy. Fourteen percent (122/874) have ≥1 WHO-defined mutation, of which 98% (120/122) are NNRTI mutations. Rates of virologic suppression are lower in the total cohort among those with PDR 65% (73/112) compared to those without PDR (85% [605/713], P < 0.001), and for those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen 0.49). Results are similar in multivariable models adjusted for clinical characteristics and adherence. NNRTI resistance prior to treatment is associated with long-term failure of integrase inhibitor-containing first-line regimens, and portends high rates of first-line failure in sub Saharan Africa. Here the authors combine next generation sequencing on plasma from participants of the ADVANCE clinical trial with virological and follow-up data to investigate the impact of pre-treatment drug resistance (PDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) on the efficacy of second-generation integrase inhibitors and find an association between NNRTI resistance prior to treatment and long-term treatment.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 45 / 45/88 / 631/326/596/1787 / 692/4017 / Adult / Africa South of the Sahara / Anti-HIV Agents - therapeutic use / Cohort Studies / Drug resistance / Drug Resistance, Viral / Female / HIV / HIV Infections - drug therapy / HIV Infections - virology / HIV Integrase - genetics / HIV Integrase - metabolism / HIV Integrase Inhibitors - administration & dosage / HIV Reverse Transcriptase - genetics / HIV Reverse Transcriptase - metabolism / HIV-1 - drug effects / HIV-1 - enzymology / HIV-1 - genetics / Human immunodeficiency virus / Humanities and Social Sciences / Humans / Impact resistance / Inhibitors / Integrase / Male / multidisciplinary / Mutation / Next-generation sequencing / Non-nucleoside reverse transcriptase inhibitors / Pretreatment / RNA-directed DNA polymerase / Science / Science (multidisciplinary) / Viral Load - drug effects